Table 4. Associations of single htSNP in MDM2 and PPP1R13L and CD3EAP with lung cancer riska,b.
| Gene/rsCa/Co | Co–dominant(AB vs. AA)/(BB vs. AA)/P | Dominant (AB + BB vs. AA)/P | Recessive (BB vs. AA + AB)/P | Log–additive– –/P |
|---|---|---|---|---|
| MDM2 | ||||
| rs1690924(A>G) | ||||
| 571/568 | 1.24 (0.96–1.59)/1.24 (0.77–2.00)/0.22 | 1.24 (0.97–1.57)/0.08 | 1.14 (0.71–1.83)/0.58 | 1.17 (0.97–1.42)/0.11 |
| rs1846402(G>T) | ||||
| 608/603 | 1.20 (0.93–1.56)/0.74 (0.35–1.59)/0.25 | 1.16 (0.90–1.48)/0.25 | 0.70 (0.33–1.50)/0.36 | 1.09 (0.87–1.36)/0.46 |
| rs2291857(C>A) | ||||
| 611/613 | 1.17(0.92–1.49)/1.02 (0.69–1.51)/0.42 | 1.14 (0.91–1.43)/0.26 | 0.94 (0.65–1.37)/0.76 | 1.06 (0.90–1.27)/0.47 |
| rs3730581(A>G) | ||||
| 613/621 | 1.18 (0.90–1.55)/0.99 (0.72–1.36)/0.35 | 1.11 (0.86–1.44)/0.42 | 0.89 (0.68–1.16)/0.39 | 1.00 (0.85–1.17)/0.99 |
| rs3730635(A>G) | ||||
| 612/625 | 1.24 (0.74–2.10)/NA (0.00–NA)/0.17 | 1.32 (0.79–2.21)/0.29 | NA (0.00–NA)/0.092 | 1.37 (0.84–2.26)/0.21 |
| PPP1R13L | ||||
| rs1970764(A>G) | ||||
| 594/590 | 1.06 (0.79–1.40)/1.39(0.99–1.94)/0.11 | 1.15 (0.88–1.50)/0.32 | 1.34 (1.02–1.76)/0.037c | 1.18 (0.99–1.39)/0.057 |
| CD3EAP | ||||
| rs967591(G>A) | ||||
| 594/590 | 1.31 (1.01–1.70)c/1.28 (0.92–1.78)/0.11 | 1.30 (1.01–1.67)/0.038c | 1.09 (0.81–1.45)/0.58 | 1.15 (0.98–1.35)/0.092 |
| rs735482(A>C) | ||||
| 603/595 | 1.13 (0.87–1.48)/1.14 (0.82–1.57)/0.62 | 1.13 (0.88–1.46)/0.32 | 1.05 (0.79–1.39)/0.73 | 1.07 (0.91–1.26)/0.4 |
a, Dominant model: AB (Heterozygote) + BB (Homozygous variant-type) versus AA (Homozygous wild-type), Recessive model: BB versus AA + AB, Co-dominant model: AB versus AA and BB versus AA, Log-additive model: analysis of trend where AA is ‘0’, AB is ‘1’ and BB is ‘2’; b, OR (95% CI), adjusted for smoking duration; c, statistical significance.